Status:
COMPLETED
Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis
Lead Sponsor:
Spirig Pharma Ltd.
Conditions:
Skin Alterations Associated With Atopic Dermatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis
Eligibility Criteria
Inclusion
- Informed consent
- Atopic Dermatitis Patients with SCORing Atopic Dermatitis (SCORAD) ≤ 40
- Atopic lesion localisation: arms; additional legs, neck
Exclusion
- SCORAD \> 40
- Unstable, uncontrolled medical status (e.g. active systemic or topical infection)
- Active immunosuppression or cancer
- Narcotics- or Alcohol abuse
- Participation in another clinical trial until one month prior inclusion
- Known allergies against an ingredient of the investigational medicinal product
- Different periods of grace for certain pre-treatments, e.g. topical corticosteroids, immune modulating drugs
- Pregnancy or lactation
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01792713
Start Date
February 1 2013
End Date
February 1 2014
Last Update
May 20 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsmedizin Charité Berlin, Abteilung für Dermatologie und Allergologie
Berlin, Germany, 10117
2
Universitätsklinikum Münster, Klinik für Hautkrankheiten
Münster, Germany, 48149